Hyperplasia Evaluation and Management of BPH - Review of Current Guidelines and Innovations

<h2 id="key-points">Key Points</h2><ul><li>Evaluation of LUTS/BPH is emphasized to be personalized and algorithm-based, with risk stratification playing a important role in guiding management decisions.</li><li>Medical management remains the preferred first-line approach, with greater use of combination regimens and newer agents tailored to symptom patterns and patient preferences.</li><li>Minimally invasive surgical therapies provide effective symptom relief with lower risk profiles, making appropriate patient selection essential.</li><li>Choice of definitive surgical treatment depends on prostate size, symptom severity, and comorbidities, with emerging technologies such as robotic waterjet therapy gaining wider adoption.</li></ul><h2 id="evaluation">Evaluation Of LUTS/BPH</h2><ul><li><strong>Initial evaluation of LUTS suspected to be due to BPH includes,</strong><ul><li>Medical history</li><li>Physical examination</li><li>Symptom quantification using the International Prostate Symptom Score (IPSS)</li><li>Associated quality-of-life question.</li></ul></li><li>The IPSS differs from the AUA Symptom Index (AUA-SI), which assesses the same seven urinary symptoms but excludes the quality-of-life component.</li><li>Advanced imaging techniques, including multiparametric MRI and transrectal ultrasound (TRUS), improve assessment of prostate volume and morphology.</li><li>Personalized diagnostic pathways incorporate uroflowmetry and postvoid residual measurements to evaluate obstruction severity, while urodynamic studies for complex bladder function test.</li><li>Management follows AUA guideline-based algorithms but must remain individualized, recognizing that LUTS may have multifactorial causes and are not always attributable to prostate enlargement (e.g., nocturia due to obstructive sleep apnea).</li></ul><h2 id="medical-management">Medical Management of LUTS/BPH</h2><ul><li>Alpha blockers such as<strong> tamsulosin and silodosin remain first-line treatments</strong>, offering rapid symptom relief by relaxing prostatic smooth muscle and reducing bladder outlet resistance.</li><li>The more selective alpha blockers such as <strong>tamsulosin, alfuzosin, and silodosin</strong> have less orthostatic hypotension.</li><li>The Medical Therapy of Prostate Symptoms (MTOPS) trial demonstrated that 5-ARIs, such as <strong>finasteride and dutasteride</strong>, significantly reduce the risk of AUR and the need for surgical intervention over a 4-year period.</li><li><strong>5-ARIs</strong> are recommended for patients with significant prostatic enlargement (&gt;30 g), PSA &gt; 1.5 ng/mL or palpable enlargement on digital rectal examination with an average drop in 15% to 25% PV.</li><li>As glandular component of prostate tissue decrease, PSA production typically drops by 50% but keeping free/total PSA ratio constant.</li><li><strong>Combination therapy with alpha blockers and 5-ARIs</strong>, as highlighted in the MTOPS and combination of dutasteride and tamsulosin (CombAT) trial, provides superior symptom relief and prevents disease progression more effectively than monotherapy, particularly in patients with prostates larger than 30 g.</li><li>For patients with bothersome storage symptoms in the moderate to severe range, combination use of <strong>anticholinergic agents or beta-3-agonists</strong> with an alpha blocker can be considered.</li><li>Preference is usually given for use of beta-3-agonists such as<strong> mirabegron or vibegron</strong> considering dementia as a side effect with other anticholinergics.</li><li>Beta-3 agonists, such as <strong>mirabegron</strong>, used as monotherapy or in combination are increasingly utilized to target storage symptoms, particularly in patients experiencing nocturia and urgency incontinence.</li><li>Phosphodiesterase-5 inhibitors, such as <strong>tadalafil</strong>, have gained recognition for their dual benefit in treating LUTS and erectile dysfunction.</li><li>Multiple studies have demonstrated that daily<strong> tadalafil 5 mg</strong> improves urinary symptoms likely by smooth muscle relaxation in the prostate and bladder neck.</li><li>AUR management is also included in the AUA BPH Guidelines as numerous trials have been performed to study AUR in men.</li><li><strong>Recommendations in the AUA BPH guidelines now include that men in urinary retention related to BPH should be prescribed an oral alpha blocker agent.</strong></li></ul><figure class="image"><img style="aspect-ratio:865/610;" src="https://cdn.megawecare.com/GHBY/Internal-Images/algorithm-on-evaluation-and-management-of-luts-bph.webp" alt="Algorithm on evaluation and management of LUTS/BPH" width="865" height="610"></figure><h2 id="surgical-approach">Surgical Approach</h2><ul><li>While majority of patients will opt or remain on medical therapy, there are circumstances in which an invasive approach is indicated.</li><li>This occurs when lifestyle, medical, or nonprocedure based approaches fail to address patients bother- some urinary symptoms or if there is evidence of progression of BPH, BOO and bladder dysfunction.</li></ul><figure class="image"><img style="aspect-ratio:1398/571;" src="https://cdn.megawecare.com/GHBY/Internal-Images/surgical-management-algorithm-based-on-prostate-size.webp" alt="Surgical Management Algorithm Based On Prostate Size" width="1398" height="571"></figure><h2 id="conclusion" data-section="conclusion">Conclusion</h2><h3>Pearls</h3><ul><li>Use International Prostate Symptom Score +QoL score to quantify symptom severity and guide treatment decisions; differentiate from American Urologic Association symptom index which omits the QoL question.&nbsp;</li><li>Alpha blockers provide rapid symptom relief; use selective agents (eg, tamsulosin and silodosin) to minimize hypotension, especially in elderly or comorbid patients.</li><li>5-ARIs are best for prostates &gt; 30 g or prostatespecific antigen &gt; 1.5 ng/mL, with proven benefit in reducing AUR and need for surgery (MTOPS and CombAT trials).</li><li>Beta-3 agonists (eg, mirabegron) are preferred over anticholinergics in elderly patients due to lower dementia risk.</li><li>Prostatic urethral lift and WVTT preserve sexual function and are ideal for prostates 30-80 g, with WVTT effective in median lobe obstruction.</li><li>Holmium laser enucleation of the prostate and robotic simple prostatectomy are most durable for large prostates (&gt;150 g), with lower retreatment rates than PVP or transurethral resection of prostate.</li></ul><h3>Pitfalls</h3><ul><li>Do not assume all LUTS are due to BPH-rule out other causes like obstructive sleep apnea (for nocturia), overactive bladder, or neurologic dysfunction.</li><li>Warn patients on alpha blockers about intraoperative floppy iris syndrome and communicate with ophthalmologists prior to cataract surgery.</li><li>Avoid anticholinergics in older adults due to risk of cognitive decline and urinary retention.</li><li>Post finasteride syndrome is controversial but should be acknowledged when counseling patients starting 5-ARIs.</li><li>Avoid overuse of surgery in asymptomatic or uncomplicated bladder outlet obstruction; observation is often appropriate.</li><li><strong>5-ARIS:</strong> 5-alpha reductase inhibitors; AUA: American Urological Association; AUR: Acute Urinary retention; BOO: Bladder outlet obstruction; BPH: Benign prostatic hyperplasia; LUTS: Lower urinary tract symptoms; PSA: prostate-specific antigen; PV: prostate volume</li></ul>

Urology Update 2   Issue 1   Jan 2026

<ul><li><a href="#key-points">Key Points</a></li><li><a href="#evaluation">Evaluation Of LUTS/BPH</a></li><li><a href="#medical-management">Medical Management of LUTS/BPH</a></li><li><a href="#surgical-approach">Surgical Approach</a></li><li><a href="#conclusion">Conclusion</a></li></ul>

Hyperplasia Evaluation and Management of BPH - Review of Current Guidelines and Innovations

Reference